• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » AltheRx acquires Solabegron from GSK

AltheRx acquires Solabegron from GSK

March 29, 2011
CenterWatch Staff

AltheRx, a privately-held clinical development company, has purchased all assets related to Solabegron from GlaxoSmithKline. Solabegron is a highly selective and potent beta3-adrenoceptor agonist that has demonstrated positive results in phase II clinical programs for the treatment of overactive bladder (OAB) in women and irritable bowel syndrome (IBS). Solabegron also demonstrated a favorable tolerability profile across all phase II studies.

"AltheRx's business strategy is to acquire novel products aligned with our core expertise, and efficiently advance them through development," said Shawn O'Brien, CEO of AltheRx Pharmaceuticals. "Solabegron is an outstanding primary product for AltheRx. The clinical data suggest that the novel mechanism of Solabegron has the potential to address the needs of patients suffering from OAB and IBS."

In the phase II OAB study, Solabegron was studied in 258 patients with moderate to severe incontinence experiencing an average of 4.5 wet episodes per day. Study results demonstrated a significant improvement with Solabegron as compared to placebo as measured by the reduction of the number of wet episodes and the number of voids per day. In IBS, a phase II study evaluated 102 patients indicated that Solabegron demonstrated significant reduction in pain associated with IBS and a trend for greater improvement in the quality of life compared to placebo. Both phase II studies indicated a tolerability profile for Solabegron that was similar to placebo.

    Upcoming Events

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing